Example: biology
〔1〕部位名（剖検所見） - nihs.go.jp
1 〔1〕部位名（剖検所見） 2）臓器特異的な所見 1)Adrenalgland 副腎 Accessoryadrenal 副副腎 2)Bloodvessel 血管 Aneurysm 動脈瘤
Information
Domain:
Source:
Link to this page:
Documents from same domain
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され， 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Since 1874 遺伝子治療用製品の開発における 国内 …
www.nihs.go.jp遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名： n-(2-
毒物及び劇物取締法Q＆A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q＆A 質問一覧 1．毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Related documents
症状観察用語集 A外観Generalappearance - nihs.go.jp
www.nihs.go.jpTitle 橡 Taro9-全身A.PDF Author 橡 総合評価研究室 Created Date: 12/3/1998 3:33:19 PM